全文获取类型
收费全文 | 1754篇 |
免费 | 154篇 |
出版年
2021年 | 28篇 |
2020年 | 9篇 |
2019年 | 11篇 |
2018年 | 12篇 |
2017年 | 24篇 |
2016年 | 23篇 |
2015年 | 57篇 |
2014年 | 90篇 |
2013年 | 90篇 |
2012年 | 118篇 |
2011年 | 101篇 |
2010年 | 67篇 |
2009年 | 54篇 |
2008年 | 82篇 |
2007年 | 84篇 |
2006年 | 82篇 |
2005年 | 54篇 |
2004年 | 73篇 |
2003年 | 61篇 |
2002年 | 62篇 |
2001年 | 37篇 |
2000年 | 41篇 |
1999年 | 38篇 |
1998年 | 38篇 |
1997年 | 37篇 |
1996年 | 26篇 |
1995年 | 24篇 |
1994年 | 20篇 |
1993年 | 25篇 |
1992年 | 37篇 |
1991年 | 50篇 |
1990年 | 24篇 |
1989年 | 26篇 |
1988年 | 25篇 |
1987年 | 28篇 |
1986年 | 29篇 |
1985年 | 19篇 |
1984年 | 14篇 |
1983年 | 13篇 |
1982年 | 10篇 |
1981年 | 10篇 |
1980年 | 16篇 |
1979年 | 18篇 |
1978年 | 11篇 |
1977年 | 13篇 |
1976年 | 15篇 |
1975年 | 7篇 |
1973年 | 9篇 |
1972年 | 7篇 |
1970年 | 7篇 |
排序方式: 共有1908条查询结果,搜索用时 31 毫秒
71.
P E J?rgensen T N Rasmussen P Skov Olsen L Raaberg S Seier Poulsen E Nex? 《Regulatory peptides》1990,28(3):273-281
The rat excretes around 2 nmol epidermal growth factor (EGF) in the urine per 24 h. The urinary EGF might be derived from plasma and/or might be synthesized in the kidneys. We have used the rat to study the renal uptake and excretion of homologous EGF from plasma. I.v. injected 125I-EGF was removed from the circulation within a few minutes. 5 min after the injection, the kidneys contained 12% of the 125I-EGF. The kidneys seemed to degrade most of the 125I-EGF which they accumulated from blood, as only 4% of the injected label was excreted as intact 125I-EGF in the urine. The amount of endogenous EGF in plasma was under the detection limit of our enzyme-linked immunosorbent assay (0.03 nmol/l) and it remained so after bilateral nephrectomy. Even if plasma EGF was 0.03 nmol/l excretion of EGF from plasma could account for less than 5% of the urinary EGF. This study shows that the kidneys are able to accumulate EGF from plasma and excrete a part of it as intact EGF in the urine. However, excretion of immunoreactive EGF from plasma can only account for a minor part of the urinary EGF. 相似文献
72.
73.
74.
Suzanne M. Marselis Katharine Abernethy Alfonso Alonso John Armston Timothy R. Baker Jean‐Francois Bastin Jan Bogaert Doreen S. Boyd Pascal Boeckx David F. R. P. Burslem Robin Chazdon David B. Clark David Coomes Laura Duncanson Steven Hancock Ross Hill Chris Hopkinson Elizabeth Kearsley James R. Kellner David Kenfack Nicolas Labrire Simon L. Lewis David Minor Herv Memiaghe Abel Monteagudo Reuben Nilus Michael O'Brien Oliver L. Phillips John Poulsen Hao Tang Hans Verbeeck Ralph Dubayah 《Global Ecology and Biogeography》2020,29(10):1799-1816
75.
76.
77.
Vincenzo Forgetta Gary Leveque Joana Dias Deborah Grove Robert Lyons Jr. Suzanne Genik Chris Wright Sushmita Singh Nichole Peterson Michael Zianni Jan Kieleczawa Robert Steen Anoja Perera Doug Bintzler Scottie Adams Will Hintz Volker Jacobi Louis Bernier Roger Levesque Ken Dewar 《Journal of biomolecular techniques》2013,24(1):39-49
As part of the DNA Sequencing Research Group of the Association of Biomolecular Resource Facilities, we have tested the reproducibility of the Roche/454 GS-FLX Titanium System at five core facilities. Experience with the Roche/454 system ranged from <10 to >340 sequencing runs performed. All participating sites were supplied with an aliquot of a common DNA preparation and were requested to conduct sequencing at a common loading condition. The evaluation of sequencing yield and accuracy metrics was assessed at a single site. The study was conducted using a laboratory strain of the Dutch elm disease fungus Ophiostoma novo-ulmi strain H327, an ascomycete, vegetatively haploid fungus with an estimated genome size of 30–50 Mb. We show that the Titanium System is reproducible, with some variation detected in loading conditions, sequencing yield, and homopolymer length accuracy. We demonstrate that reads shorter than the theoretical minimum length are of lower overall quality and not simply truncated reads. The O. novo-ulmi H327 genome assembly is 31.8 Mb and is comprised of eight chromosome-length linear scaffolds, a circular mitochondrial conti of 66.4 kb, and a putative 4.2-kb linear plasmid. We estimate that the nuclear genome encodes 8613 protein coding genes, and the mitochondrion encodes 15 genes and 26 tRNAs. 相似文献
78.
79.
S?s Neergaard-Petersen Ramzi Ajjan Anne-Mette Hvas Katharina Hess Sanne B?jet Larsen Steen Dalby Kristensen Erik Lerkevang Grove 《PloS one》2013,8(8)
Background
Aspirin is a cornerstone in prevention of cardiovascular events and modulates both platelet aggregation and fibrin clot formation. Some patients experience cardiovascular events whilst on aspirin, often termed aspirin treatment failure (ATF). This study evaluated both platelet aggregation and fibrin clot structure in patients with ATF.Methods
We included 177 stable coronary artery disease patients on aspirin monotherapy. Among these, 116 (66%) had ATF defined as myocardial infarction (MI) whilst on aspirin. Platelet aggregation was assessed by Multiplate® aggregometry and VerifyNow®, whereas turbidimetric assays and scanning electron microscopy were employed to study fibrin clot characteristics.Results
Enhanced platelet aggregation was observed in patients with ATF compared with non-MI patients following stimulation with arachidonic acid 1.0 mM (median 161 (IQR 95; 222) vs. 97 (60; 1776) AU*min, p = 0.005) and collagen 1.0 µg/mL (293 (198; 427) vs. 220 (165; 370) AU*min, p = 0.03). Similarly, clot maximum absorbance, a measure of fibrin network density, was increased in patients with ATF (0.48 (0.41; 0.52) vs. 0.42 (0.38; 0.50), p = 0.02), and this was associated with thinner fibres (mean ± SD: 119.7±27.5 vs. 127.8±31.1 nm, p = 0.003) and prolonged lysis time (552 (498; 756) vs. 519 (468; 633) seconds; p = 0.02). Patients with ATF also had increased levels of C-reactive protein (CRP) (1.34 (0.48; 2.94) and 0.88 (0.32; 1.77) mg/L, p = 0.01) compared with the non-MI group. Clot maximum absorbance correlated with platelet aggregation (r = 0.31–0.35, p-values<0.001) and CRP levels (r = 0.60, p<0.001).Conclusions
Patients with aspirin treatment failure showed increased platelet aggregation and altered clot structure with impaired fibrinolysis compared with stable CAD patients without previous MI. These findings suggest that an increased risk of aspirin treatment failure may be identified by measuring both platelet function and fibrin clot structure. 相似文献80.
Helle Wulf-Johansson Sofie Lock Johansson Anders Schlosser Anne Trommelholt Holm Lars Melholt Rasmussen Hans Mickley Axel C. P. Diederichsen Henrik Munkholm Tina Svenstrup Poulsen Ida Torn?e Vicki Nielsen Niels Marcussen J?rgen Vestbo Susanne Gj?rup S?kmose Uffe Holmskov Grith Lykke Sorensen 《PloS one》2013,8(12)
Microfibrillar-associated protein 4 (MFAP4) is located in the extracellular matrix (ECM). We sought to identify tissues with high levels of MFAP4 mRNA and MFAP4 protein expression. Moreover, we aimed to evaluate the significance of MFAP4 as a marker of cardiovascular disease (CVD) and to correlate MFAP4 with other known ECM markers, such as fibulin-1, osteoprotegerin (OPG), and osteopontin (OPN). Quantitative real-time PCR demonstrated that MFAP4 mRNA was more highly expressed in the heart, lung, and intestine than in other elastic tissues. Immunohistochemical studies demonstrated high levels of MFAP4 protein mainly at sites rich in elastic fibers and within blood vessels in all tissues investigated. The AlphaLISA technique was used to determine serum MFAP4 levels in a clinical cohort of 172 patients consisting of 5 matched groups with varying degrees of CVD: 1: patients with ST elevation myocardial infarction (STEMI), 2: patients with non-STEMI, 3: patients destined for vascular surgery because of various atherosclerotic diseases (stable atherosclerotic disease), 4: apparently healthy individuals with documented coronary artery calcification (CAC-positive), and 5: apparently healthy individuals without signs of coronary artery calcification (CAC-negative). Serum MFAP4 levels were significantly lower in patients with stable atherosclerotic disease than CAC-negative individuals (p<0.05). Furthermore, lower serum MFAP4 levels were present in patients with stable atherosclerotic disease compared with STEMI and non-STEMI patients (p<0.05). In patients with stable atherosclerotic disease, positive correlations between MFAP4 and both fibulin-1 (ρ = 0.50; p = 0.0244) and OPG (ρ = 0.62; p = 0.0014) were found. Together, these results indicate that MFAP4 is mainly located in elastic fibers and is highly expressed in blood vessels. The present study suggests that serum MFAP4 varies in groups of patients with different cardiovascular conditions. Further studies are warranted to describe the role of serum MFAP4 as a biomarker of stable atherosclerotic disease. 相似文献